NorthWest Biotherapeutics Inc (NWBO)

[Extremist223]

No person's investment should trump scientific progress.

A more accurate assessment would be that cancer is very heterogeneous and finding single agents that work for the entire group is difficult. That being said, because we are able to distinguish one person's cancer from another's, that is the exact reason why we would have an adaptable trial. In other words, we can prove that patients will respond differently because their cancer is genetically different. So we should run a trial on all-comers and figure out exactly who those surviving patients are, then write a journal article about those findings and seek an approval based on those biomarkers. When you know for years that you are driving positive results for patients based on the infiltration of t-cells, but that you don't yet know exactly how to pin point who those patients are, the mechanics of this trial make perfect sense.

These shorts seem to want to say that we have to run a phase 3 trial in hundreds of patients to prove efficacy, but also mad that we couldn't identify the biomarker ahead of time in trials of 20 patients. Contradictory neural network.

Everyone agrees that taking all-comers and deducing after the fact where the therapy works is more cost effective than chancing a pre-chosen biomarker from a phase 2 of 20 patients and then running a multi-hundred patient trial only to fail to the sample size of the phase 2.

DEDUCTION IS SCIENTIFIC RIGOR

Furthermore, allowing the crossover to the placebo arm certainly makes a lot of sense when you can both visually verify immune cell infiltration with MRI and have established survival curves for glioblastoma. The survival curves remain nearly unchanged even across time, but again to be as accurate as possible they are comparing to the contemporaneous period.

These doctors are working at the best institutions around the globe and they are straight up kicking ass. They have convinced me that they are creating best practice even if it takes longer than it should.

Liau has known for a long time now that she is driving positive results for patients, even if it is not all of them. I can't imagine her heartache knowing that she researched a modality that is efficacious but that she didn't have the money to run a phase 3 trial and get it approved. Her life's work is not going to hang in the balance of original endpoints when flares on the MRI from DCVAX increase survival.

They are performing a lot of work behind the scenes to prove to regulators that this therapy works.

The market makers have their AI chatbot set up to be a whiner in the face of new diagnostic tools. They don't want to hear that DCVAX can be proven to work with these tools, only that we chose endpoints and those endpoints aren't working.

They are the type of people to deny a placebo patient an active therapy, just to separate both arms and prove that a therapy works, but not actually push the boundaries of scientific knowledge and develop the tools to figure things out in even more brilliant ways. Short sellers do not actually care and therefore should be destroyed. They are the very definition of fake caring for scientific rigor.

Can you really believe that they would be upset over the decision of changing endpoints like PFS (while still blinded) when a failure of that due to a flare on MRI caused by t-cell infiltration is positive for the patient? They would throw out decades of work just to support their investment. They have had long enough to cover their position and get out before it's catastrophic for them. Instead, they fight tooth and nail over change that has already happened. Do they not realize that fighting is futile? Merck could still buy the company based on a failed trial over the whiner endpoints because they looked at said data and saw the therapy actually works. That makes their short position explode either way.

So why continue to whine? The only reason left would be American Shorts and Chinese Longs.

If the journal article comes out and through deduction they show that DCVAX is driving positive survival responses it has to get approval. If it doesn't then the FDA is acting in a capacity serving National Security and they will likely start a war.

If you are a short, you should cover immediately, because it wouldn't matter if revised endpoints were a strategy that changed the bet on you part way through. The company can run a strategy that ruins short sellers regardless of the outcome of the trial.

Funny, the FDA would say go whine to someone else about that. They'd say, we don't do that here :). Identical to responses I get from the RCMP.

I don't think we have much to worry about, either these shorts are FRIED by the FED (a flipped endpoints F U) or the shorts are the FED and China will make this work for us because if they bought millions of shares they aren't backing down

So when I go over these facts and I see HyGro show up distraught about endpoints I try to consider who is actually behind the name.

No person's investment should trump scientific progress and short selling should not even exist because it can lead to a FLAG loss and world war 3.

SOLDIERS SHOULD NOT BE LEVERAGED TO SETTLE FLAG VS FLAG STOCK MARKET FINANCIAL DISPUTES.

Finally, you can defeat shortsellers in a risk free guaranteed way and I want to be retired from NWBO's approval

When the shorts build a system where they can participate from the Cayman islands and then walk away, I don't think the Army will have any problem cleaning up THE PROBLEM.

They already walked away from America, don't let them build it like shit and play from an island.

THE FINALE FOR NWBO COULD ONLY BE BEST FINISHED BY A MASSIVE CHINESE LONG POSITION THAT IS UNTRACEABLE. FEDERAL RESERVE DESTROYED.

Money makes flags race to see who can be the biggest asshole.

"Oh you took vitamins out of the food? Well we better do it too or we'll fall behind at social security."

Leave a legacy, not a trail of shit.
I broke this girls heart, but she gets it.